White label ELPA - ClinicalTrials.eu

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Recruiting

3 1 1
Investigated Diseases:
- Prostate cancer metastatic
Investigated Drugs:
+5
Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy

Recruiting

3 1 1 1
Investigated Diseases:
- Hormone-refractory prostate cancer
Investigated Drugs:
+8
Study on the Safety and Dosage of GD2IL18CART for Patients with Relapsed or Refractory GD2 Positive Solid Cancers

Recruiting

1 1 1 1
Investigated Diseases:
Investigated Drugs:
Study on Reducing Prosthetic Joint Infection in Hip Replacement Patients Using Vancomycin, Tobramycin, and Saline-Infused Bone Graft

Recruiting

2 1 1
Investigated Diseases:
- Medical device site joint infection
Investigated Drugs:
- Vancomycin
- Saline
Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

Recruiting

3 1 1 1
Investigated Drugs:
+9
Study on the Effectiveness of Durvalumab and Bevacizumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Recruiting

3 1 1
Investigated Diseases:
- Hepatocellular carcinoma
Investigated Drugs:
Study on the Effects of Prasinezumab in Patients with Early Parkinson’s Disease

Recruiting

2 1 1
Investigated Diseases:
- Parkinson’s disease
Investigated Drugs:
- Prasinezumab
Study on the Effectiveness of Isoflurane, Propofol, and Midazolam for Sedation in Patients with Severe Brain Injuries

Recruiting

3 1 1 1
Investigated Drugs:
- Propofol
Study on Olaparib and Durvalumab for Patients with Advanced Ovarian Cancer Undergoing Surgery

Recruiting

2 1 1 1
Investigated Drugs:
- Olaparib
- Durvalumab
Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Recruiting

3 1 1 1
Investigated Drugs:
+7

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies